Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.21.2
Segment Information (Tables)
9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Schedule of segment reporting information
    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2021     2020     2021     2020  
Revenues                        
Real property operations   $ 355,459     $ 324,982     $ 925,465     $ 923,205  
Medical related consulting services     131,305      
-
      131,305      
-
 
Total     486,764       324,982       1,056,770       923,205  
Costs and expenses                                
Real property operations     215,622       135,821       637,663       663,086  
Medical related consulting services     102,442      
-
      102,442      
-
 
Total     318,064       135,821       740,105       663,086  
Gross profit                                
Real property operations     139,837       189,161       287,802       260,119  
Medical related consulting services     28,863      
-
      28,863      
-
 
Total     168,700       189,161       316,665       260,119  
Other operating expenses                                
Real property operations     76,422       77,852       256,675       291,886  
Medical related consulting services     32,239       160,557       361,067       491,683  
Development services and sales of developed products    
-
      28,002      
-
      94,241  
Corporate/Other     2,025,010       3,113,308       6,269,762       8,797,886  
Total     2,133,671       3,379,719       6,887,504       9,675,696  
Other (expense) income                                
Interest expense                                
Corporate/Other     (50,248 )     (41,531 )     (141,528 )     (126,169 )
Total     (50,248 )     (41,531 )     (141,528 )     (126,169 )
Other income (expense)                                
Real property operations     3       4       111       (927 )
Medical related consulting services     (14,173 )     (20,095 )     (49,162 )     (36,673 )
Development services and sales of developed products    
-
      221      
-
      224  
Corporate/Other     5,170      
-
      5,171      
-
 
Total     (9,000 )     (19,870 )     (43,880 )     (37,376 )
Total other expense, net     (59,248 )     (61,401 )     (185,408 )     (163,545 )
Net income (loss)                                
Real property operations     63,418       111,313       31,238       (32,694 )
Medical related consulting services     (17,549 )     (180,652 )     (381,366 )     (528,356 )
Development services and sales of developed products    
-
      (27,781 )    
-
      (94,017 )
Corporate/Other     (2,070,088 )     (3,154,839 )     (6,406,119 )     (8,924,055 )
Total   $ (2,024,219 )   $ (3,251,959 )   $ (6,756,247 )   $ (9,579,122 )

  

Schedule of real property operating
Identifiable long-lived tangible assets at September 30, 2021 and December 31, 2020   September 30,
2021
    December 31,
2020
 
Real property operations   $ 7,580,270     $ 7,697,473  
Medical related consulting services     951       223,459  
Development services and sales of developed products    
-
      243,869  
Corporate/Other     389,584      
-
 
Total   $ 7,970,805     $ 8,164,801  

 

Schedule of identifiable long-lived tangible assets
Identifiable long-lived tangible assets at September 30, 2021 and December 31, 2020   September 30,
2021
    December 31,
2020
 
United States   $ 7,632,088     $ 7,764,947  
China     338,717       399,854  
Total   $ 7,970,805     $ 8,164,801